Gastric cancer (GC) is one of the most common malignancies worldwide. It is particularly challenging due to common detection at the advanced stages of the diseases preventing potential therapeutic and treatment strategies for patients. Common forms of treatment include chemotherapy which has been found to improve the survival rate and overall quality of life for patients with unresectable, locally advanced or at the metastatic stages of the disease. However, chemotherapy has also proven to cause significant side effects in some patients.
Lymphatic metastasis has been found to be common in gastric cancer patients. Lymph vascular invasion (LVI) has been identified to be associated to the infiltration of tumor cells in the arteries, veins or lymphatic vessels. This has been identified to prompt local recurrence and the distant metastasis of various tumors. This has led to the LVI status as an independent prognostic factor and studies have found the occurrence of pathological LVI is associated with gastric cancer progression and linked to poor clinical prognosis and low survival rate.
There have been advances in radiomics applied in gastric cancer which is utilized to provide an analysis of the tumor, how it develops and responds to the treatment provided. Currently, 18F-fluorodeoxyglucose(18F-FDG) positron emission tomography-computed tomography (PET-CT) is an imaging tool which has been demonstrated to play a key role in pre-operative staging and provides valuable information including the location, size and blood supply of the tumor. Radiomics based on CT images has been found to provide a more accurate representation by extracting quantitative characteristics based on the shape and size of tumor.
This Research Topic aims to generate a discussion of how radiomics is applied in gastric cancer and the impact it has on early detection and prevention. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Gastric cancer (GC) is one of the most common malignancies worldwide. It is particularly challenging due to common detection at the advanced stages of the diseases preventing potential therapeutic and treatment strategies for patients. Common forms of treatment include chemotherapy which has been found to improve the survival rate and overall quality of life for patients with unresectable, locally advanced or at the metastatic stages of the disease. However, chemotherapy has also proven to cause significant side effects in some patients.
Lymphatic metastasis has been found to be common in gastric cancer patients. Lymph vascular invasion (LVI) has been identified to be associated to the infiltration of tumor cells in the arteries, veins or lymphatic vessels. This has been identified to prompt local recurrence and the distant metastasis of various tumors. This has led to the LVI status as an independent prognostic factor and studies have found the occurrence of pathological LVI is associated with gastric cancer progression and linked to poor clinical prognosis and low survival rate.
There have been advances in radiomics applied in gastric cancer which is utilized to provide an analysis of the tumor, how it develops and responds to the treatment provided. Currently, 18F-fluorodeoxyglucose(18F-FDG) positron emission tomography-computed tomography (PET-CT) is an imaging tool which has been demonstrated to play a key role in pre-operative staging and provides valuable information including the location, size and blood supply of the tumor. Radiomics based on CT images has been found to provide a more accurate representation by extracting quantitative characteristics based on the shape and size of tumor.
This Research Topic aims to generate a discussion of how radiomics is applied in gastric cancer and the impact it has on early detection and prevention. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.